Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON48669
NL-OMON48669
Completed
Not Applicable

Early response evaluation with 18F-FDG PET/CT and immunological profiling of circulating immune cells and tumor-draining lymph nodes in non-small cell lung cancer patients treated with immunotherapy. - Early response evaluation in NSCLC patients treated with immunotherapy

Antoni van Leeuwenhoek Ziekenhuis0 sites50 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Antoni van Leeuwenhoek Ziekenhuis
Enrollment
50
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational invasive

Investigators

Sponsor
Antoni van Leeuwenhoek Ziekenhuis

Eligibility Criteria

Inclusion Criteria

  • •In order to be eligible to participate in this study, a subject must meet all
  • •of the following criteria:
  • •\* willing and able to provide written informed consent for the study.
  • •\* \* 18 years of age on day of signing informed consent.
  • •\* confirmed diagnosis of NSCLC.
  • •\* Histological tumor biopsy for PD\-L1 IHC assessment (DAKO assay) available.
  • •\* Eligible for first line chemo\-immunotherapy or 2nd line and beyond PD\-(L)1
  • •immunotherapy monotherapy.
  • •\* Measurable disease according to RECIST v1\.1\.
  • •\* WHO performance status of 0\*2\.

Exclusion Criteria

  • •A potential subject who meets any of the following criteria will be excluded
  • •from participation in this study:
  • •\* Has had prior chemotherapy, targeted small molecule therapy, or radiation
  • •therapy within 2 weeks prior to the baseline PET\-scan.
  • •\* Has an active infection or had an active infection within 2 weeks prior to
  • •baseline PET\-scan.
  • •\* Has a known history of hypersensitivity to contrast material.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
A retrospective study using 18F-FDG-PET/CT for the prediction of immunotherapy-related interstitial lung disease in lung cancer.Advanced or recurrent lung cancer
JPRN-UMIN000053550iigata University Medical and Dental Hospital165
Active, not recruiting
Not Applicable
Evaluation of 18F-FDHT PET/CT as an early treatment response marker in patients with metastasized castration-resistant prostate cancer to be treated with enzalutamide.Castration-resistant prostate cancerTherapeutic area: Diseases [C] - Male diseases of the urinary and reproductive systems [C12]
EUCTR2012-005431-86-NLniversity Medical Center Groningen
Completed
Not Applicable
Evaluation of early prediction using 18F-FDG PET/CT for patients with Iodine-131 refractory differentiated thyroid carcinoma treated with lenvatinibdifferentiated thyroid carcinoma
JPRN-UMIN000022592Department of Medical Oncology, Hokkaido University Graduate School of Medicine22
Completed
Not Applicable
Evaluation of 18F-FDG-PET/CT in the diagnosis and treatment response of bone metastasis.bone metastasis
JPRN-UMIN000005866ational Cancer Center Research Projects Management expenses Grants from the Government to National Cancer Research Center220
Recruiting
Not Applicable
Response prediction of third-line cetuximab-based therapy for patients with metastatic colorectal cancer using Fludeoxyglucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT)Metastatic colorectal cancer receiving third-line therapy with cetuximabCancer - Bowel - Back passage (rectum) or large bowel (colon)
ACTRN12612000052831Chang Gung Memorial Hospital30